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Introduction 
Aspirin has a variety of pharmacologic actions, which are expressed at 
different doses of the drug. An effect on platelet function occurs at very 
low doses of aspirin (1,2). Indeed, a large number of clinical trials have 
been carried out to assess whether low to moderate doses of aspirin (180 to 
1500 mg per day) taken prophylactically will affect the natural history of a 
variety of diseases in which thrombosis is thought to play a role (3). 
High doses of aspirin - similar to those taken to achieve an antiinflam- 
matory effect - have been demonstrated to acetylate plasma albumin, both in 
- vivo (4) and in vitro (5,6). -- 
ability to bind some drugs, 
Acetylation by aspirin alters albumin's 
such as phenylbutazone and flufenamic acid (7), 
and may lead to a reduced survival in plasma of prostaglandins (8) and 
thromboxane A2 (9). Such alterations in the ability of albumin to transport 
drugs and other substances may have important consequences if a large propor- 
tion of the population were taking low or moderate doses of aspirin 
prophylactically. We, therefore, undertook the following study to evaluate 
the acetylation of plasma proteins at low doses of aspirin. 
Methods 
A pool of plasma anticoagulated with 5.8 mM ethylenediaminetetraacetic 
acid was collected during the isolation of human platelets (10). This pool 
was frozen in aliquots and used in the following studies. A sample of pooled 
human serum was obtained from Dr. Peter Nowell. Purified albumin preparations 
were obtained from Worthington Biochemical and Sigma Chemical. Indomethacin 
and salicylic acid were obtained from Sigma Chemical. [3H-acetyl]aspirin 
(specific activity 200 mCi/mmole), was prepared by the method of Roth and 
Mfjerus (11). 3H-Toluene was purchased from Amersham Radiochemicals. 
[ C-carboxyllaspirin (specific activity 33 mCi/nnnole) was purchased from 
New England Nuclear. Aminohexyl Sepharose 4B was purchased from Pharmacia. 
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Ampholines, pH 3-10, were obtained from LKB Broma. Rabbit anti-human albumin 
was purchased from Calbiochem-Behring. All other chemicals were of reagent 
grade. 
Prior to acetylation plasma was dialyzed against Dulbecco's phosphate 
buffered saline (PBS, 12) for 24 hours. Purified albumins were acetylated as 
solutions in PBS. Plasma or albumin was mixed with aspirin at 37" C. At 
appropriate intervals samples were taken and were made 4% in sodium dodecyl 
sulfate and 0.05 M in 2-mercaptoethanol. These samples were heated to 100" C 
for 5 minutes and subjected to polyacrylamide gel electrophoresis (SDS-PAGE) 
according to the method of Weber and Osborn (13). Tritium incorporation into 
proteins was quantitated by a previously published method (2). Activities 
were estimated using 3H-toluene as an internal standard. 
Isoelectric focusing was carried out using the method of Baumann and 
Chrambach (14). Proteins were acetylated in 0.01 M phosphate, pH 7.0, and 
were focused on 5% T, 15% C acrylamide gels crosslinked with N,N'diallyl- 
tartardiamide in the presence of 2% NP-40. The pH of each gel was measured 
with a microelectrode, and radioactivity was quantitated as described (2). 
Affinity columns were prepared by the method of Cambiaso et al (15), using -- 
0.25% glutaraldehyde in 0.1 M sodium carbonate/bicarbonate, pH 8.5. Protein 
concentrations were assayed by the method of Lowry, et al (16), with bovine -- 
serum albumin as standard. Albumin was measured by densitometry following 
cellulose acetate electrophoresis. Fatty acids bound to purified albumin 
were assayed by the method of Evenson and Deutsch (17), using stearic acid 
as standard. 
Results 
The incubation of serum or plasma with [3H-acetyl]aspirin results in one major 
peak of radioactivity following SDS-PAGE (Fig. 1). Similar incubations of plas- 
ma with [ 14C-carboxyl]a;pirin yield no radiolabeled proteins following SDS-PAGE 
and indicate that the [ H-acetyllaspirin is acetylating a protein or proteins 
1500 r 
FIGURE 1 
Tritium incorporation into 
I 
plasma protein following 
incubation with 100~ M aspirin 
and electrophoresis as 
described in Methods. Counts 
c - 
per minute (CPM) per 2 mm 
P 
gel slice are plotted versus 
gel slice, numbered from 
M - top of gel. 
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in plasma. Solutions of purified albumin acetylated under similar conditions 
demonstrated an indistinguishable pattern of radioactivity following SDS-PAGE. 
Furthermore, when samples of serum were acetylated and subjected to isoelectric 
focusing in the presence and absence of 9 M urea, only a single band of radio- 
activity was demonstrated with p1 identical to that of a similarly acetylated 
purified albumin control. Occasionally a small band of radioactivity was seen 
near the top of our SDS-PAGE gels (Fig. 1). This was interpreted as represen- 
ting albumin dimers, as only one acetylated protein was present on the iso- 
electric focusing gels. Samples of acetylated plasma were also chromatographed 
on aminohexyl Sepharose columns coupled with rabbit antihuman albumin or normal 
rabbit serum. Greater than 90% of the radioactivity in plasma bound to the 
antihuman albumin column and was subsequently eluted with 3H sodium thiocyanate 
and 5M guanidine hydrochloride. Only 10% of the radioactivity in plasma was 
bound by a column prepared with normal rabbit serum. We conclude that albumin 
is the only plasma protein acetylated in plasma under these conditions. 
The rate of acetylation of dialyzed plasma or comparable concentrations 
of albumin is illustrated in Figure 2. The rate is not linear, but does not 
conform to that expected of a second order irreversible reaction. This may be 
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FIGURE 2 
Rate of albumin acetylation by 100 uM aspirin. A: dialyzed plasma; 
B: purified albumin, 32 mg/ml in PBS. 
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due to the fact that more than one site is being acetylated. After exposure 
to 100 nM aspirin for 90 minutes, approximately 2% of the albumin present in 
plasma is acetylated. We observed only small differences between dialyzed 
plasma, serum, and purified albumins with respect to the rate or extent of 
acetylation under these conditions. Specifically, there was no difference in 
acetylation of fatty acid free albumin versus crystallized albumins contain- 
ing varying amounts of bound fatty acid. 
Acetylation of albumin in 
of plasma in PBS treated with [ s 
lasma is a saturable process. A 0.1% solution 
H-acetyllaspirin reached a maximum acetylation 
of 1.5 moles acetyl residues per mole albumin at 180 minutes, and did not 
change over the following 24 hours. A solution of purified albumin treated in 
a similar fashion reached a maximum acetylation of 1.8 moles acetyl residues 
per mole albumin. Furthermore, a ten-fold excess of unlabeled aspirin in- 
hibits tritium uptake in plasma by 94% (Fig. 3). The concurrent presence of 
100 nM indomethacin causes a 96% inhibition of the acetylation of dilute 
plasma by 100 pM aspirin (Fig. 3). 
FIGURE 3 
Inhibition of tritium incor- 
poration by excess unlabeled 
aspirin or by indomethacin. 
Plasma was diluted in PBS to 
2% (v:v) and treated with 
100 nM radioactive aspirin. 
Squares: radioactive aspirin 
alone; circles: radioactive 
aspirin plus 10 mM unlabeled 
aspirin; triangles: radio- 
active aspirin plus 100 nM 
indomethacin. 
Time, minutes 
DISCUSSION 
Following ingestion of 650 mg aspirin, plasma aspirin levels peak at approx- 
imately 120 nM 20 minutes after ingestion and fall to undetectable levels 
by 120 minutes (18). We have studied the in vitro acetylation of plasma -- 
proteins using 100 PM aspirin over 90 minutes to approximate plasma exposure 
to aspirin in vivo during prophylactic therapy with small daily doses of -- 
aspirin. Plasma was dialyzed against PBS to avoid changes in pH during 
in vitro acetylation, as changes in pH markedly alter the rate of acetylation -- 
of amino groups (19). Although a number of plasma proteins and other macro- 
molecules are acetylated by aspirin under more rigorous conditions (20), only 
albumin is acetylated under the conditions of our study. It is interesting 
that the concurrent presence of 100 nM indomethacin inhibits the rate of 
acetylation of albumin in plasma by 96%. This suggests that these drugs bind 
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to related sites on albumin. One may also note from the present study that a 
biological effect shared by aspirin and indomethacin should not be interpreted 
a priori as an effect on fatty acid cyclooxygenase, as the drugs share other 
characteristics besides their ability to inhibit this enzyme. 
The rate of albumin acetylation we measure would be sufficient to 
acetylate albumin completely in approximately two months of daily low dose 
aspirin ingestion, assuming an albumin half life of 17 days and no prefer- 
ential metabolism of acetylated albumin. Since certain drugs bind differently 
to acetylated albumin, albumin's function as a transporter of anions may be 
altered in patients on aspirin prophylaxis. The half life of thromboxane A2 
is much shorter in the presence of acetylated albumin than in the presence of 
native albumin (9). Furthermore prostaglandins also bind to albumin, and this 
binding may be reduced following aspirin therapy (8). Therefore, chronic 
aspirin therapy may exert an antithrombotic effect by altering plasma throm- 
boxane/prostaglandin ratios as well as acting as an antiplatelet agent. 
It is doubtful that chronic low-dose aspirin ingestion will result in any 
serious toxicity. However, there may be detrimental effects of chronic 
aspirin ingestion that are currently unrecognized (21). The recognition of 
aspirin's effects, such as its ability to acetylate albumin, may be important 
in the evaluation of patients using the drug as a chronic prophylaxis. 
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